Immunogenicity Prediction
Fasten your research & Satisfy all needs ! To address drug immunogenicity at any stage, we have developed Sensitive Immunogenicity Assessment Technology (SIAT) according to specific FDA and EMA guidelines. SIAT-based highly sensitive techniques are efficacious in biopharmaceutical quantification, antidrug antibody (ADAs) assays, and pharmacokinetic efficacy measurements.
In Silico Assessment - T Cell Epitope Screening A proprietary T cell epitope screening tool has been used to identify epitopes in biotherapeutic proteins and new antibody targets. This in silico tool can predict potential peptide/HLA binding by mimicking the structural features of MHC class II and determine binding affinity, which are prerequisites for T cell activation.
In Vitro Screening u u u u u u
Dendritic cell activation Cytokine release MHC-related peptide proteomics T cell response B cell response Cell binding and cell killing assay
In Vivo Screening In vivo immunogenicity assessments use a variety of animal models as below to display the most direct evaluation of the molecules before clinical trials. u
HLA transgenic mice
u
Humanized mice
Highlights 1. Multi-parameter measurement by flow cytometry 2. High-throughput process capable of running large sample plates 3. Strict quality control to ensure consistent and traceable sample analysis 4. Highly diverse, high quality PBMC samples from healthy donors
Creative Biolabs Confidential
12